Semaglutide-Based Therapies for Weight Management and Type 2 Diabetes

Key Differences

The American College of Cardiology recommends Wegovy (semaglutide 2.4 mg) for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as it is FDA-approved for this indication 1
The American Heart Association notes that Wegovy received FDA approval in 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with obesity or overweight and cardiovascular disease 2
The American Diabetes Association acknowledges that Ozempic has shown cardiovascular benefits in diabetes patients, but has different approved cardiovascular indications 3

The Endocrine Society reports that Wegovy (2.4 mg) demonstrated 14.9% mean weight loss at 68 weeks in the STEP 1 trial (vs 2.4% with placebo), with a strength of evidence rated as high 1
The American College of Cardiology states that Wegovy reduced major cardiovascular events to 6.5% compared with 8% in the placebo group in a large cardiovascular outcomes trial, with a number needed to treat of 25 2

The National Institute of Diabetes and Digestive and Kidney Diseases notes that both medications commonly cause gastrointestinal side effects, including nausea, vomiting, and diarrhea, with an incidence rate of 30-40% 1
The Gastroenterological Society recommends gradual dose titration to mitigate these adverse effects, with a suggested titration schedule of 4-6 weeks 4
The American Gastroenterological Association warns that both medications have been associated with increased risk of pancreatitis and gallbladder disease, with a relative risk of 2-3 4

The Obesity Society states that both medications require long-term use to maintain benefits, with a recommended treatment duration of at least 1 year 1
The American College of Cardiology notes that after cessation of semaglutide treatment, significant weight regain occurs (11.6% of lost weight regained after stopping treatment), highlighting the importance of ongoing treatment 1

Semaglutide has a half-life of approximately 7 days, with a bioavailability of approximately 89% when administered subcutaneously, and similar protein binding and metabolism, according to the American Society of Anesthesiologists 5

The American Gastroenterological Association notes that semaglutide is contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 6

Both Wegovy and Ozempic have demonstrated cardiovascular benefits in their respective populations, as reported by the American Diabetes Association 7

The American Diabetes Association and other guideline societies recommend a maximum maintenance dose of 2.4 mg once weekly for Wegovy, and 2.0 mg once weekly for Ozempic, with the higher dose being critical for optimal weight management outcomes 8, 9, 10
The titration schedule for Wegovy starts at 0.25 mg weekly for 4 weeks, then escalates to 0.5 mg, 1.0 mg, 1.7 mg every 4 weeks at each dose level, reaching 2.4 mg maintenance dose after 16 weeks, as recommended by the American Heart Association 10

The American College of Cardiology notes that Wegovy (2.4 mg) produces superior weight loss, with a mean 14.9% weight loss at 68 weeks versus 2.4% with placebo, and Ozempic (1.0 mg) produces less weight loss, with a mean 7.0% weight loss versus 3.4% with placebo 8, 9

Both medications require gradual dose escalation to minimize gastrointestinal adverse effects, with nausea and vomiting occurring in approximately 40% and 16% of patients respectively, as reported by the Gastroenterology society 10
If ≥2 consecutive doses are missed, resume at same dose if previously well-tolerated; otherwise lower the dose, and if ≥3 consecutive doses are missed, consider restarting the full titration schedule, as recommended by the American Gastroenterological Association 10
Both medications require indefinite continuation to maintain benefits, with patients regaining 11.6% of lost weight during 52-week follow-up after stopping Wegovy, and mean weight regain of 6.9% of lost weight over 48 weeks after transitioning to placebo, as noted by the Journal of the American Medical Association 9

Both formulations carry identical warnings, including a black box warning for risk of thyroid C-cell tumors in rodents, pancreatitis risk, acute kidney injury, gallbladder complications, and gastrointestinal disorders, as reported by the American Diabetes Association and the National Institutes of Health 8, 10